Arbutus Biopharma Corporation ABUS Contingent Consideration Liability (Non-Current)
Contingent Consideration Liability (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's contingent consideration liability (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's contingent consideration liability (non-current)?
- Arbutus Biopharma Corporation (ABUS) reported contingent consideration liability (non-current) of $8.6M in Q1 2026.
- How has Arbutus Biopharma Corporation's contingent consideration liability (non-current) changed year-over-year?
- Arbutus Biopharma Corporation's contingent consideration liability (non-current) decreased by 18.2% year-over-year, from $10.52M to $8.6M.
- What is the long-term trend for Arbutus Biopharma Corporation's contingent consideration liability (non-current)?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's contingent consideration liability (non-current) has grown at a 19.6% compound annual growth rate (CAGR), from $3.43M to $8.4M.
- What does contingent consideration liability (non-current) mean?
- This represents the non-current portion of estimated future payments owed to sellers as part of a business acquisition, typically triggered by the achievement of specific clinical, regulatory, or commercial milestones. It reflects the fair value of potential earn-out obligations that are expected to be settled beyond the next twelve months. Changes in this balance often indicate shifts in the probability or timing of achieving key development goals for acquired assets.